Professor and Director Dan Peer
Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice President for Research and Development in Tel Aviv University. From 2017, he is the Founding and Managing Director of the SPARK program, Center for Translational Medicine at TAU.Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) as drug discovery tools in immune cells. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA in animals. This strategy has enormous implications in cancer, inflammation, and infectious diseases. His lab developed one of the largest lipid library with unique properties and strategies to immobilized natural ligands and antibodies on the surface of lipid nanoparticles (LNPs) for cell specific delivery of RNA payloads.
His lab was also the first to show systemic, high efficiency, cell specific, therapeutic genome editing in cancer. Recently, his lab also showed the first bacterial mRNA vaccine that opened new potential field of increasing the arsenal of vaccines against antibiotic resistance strains.
Prof. Peer has more than 150 pending and granted patents. More than 60% of them have been licensed to several pharmaceutical companies and biotech and his innovations have now been tested in more than 10 different clinical trials (including the first circRNA in the clinic). In addition, based on his lab work, four spin-off companies were generated (one was sold in May 2021) aiming to bring innovative personalized medicine into clinical practice. He is a scientific advisory board member in more than 15 companies and on the scientific advisory board of more than 20 journals. In 2014, he was elected to the Israel Young Academy. In 2023, he was elected as an International Member to the US National Academy of Engineering. In 2024, he was elected Fellow, US National Academy of Inventors and in 2025, elected Fellow, of the Controlled Release Society. In 2025, he is also ranked “highly cited” in top 0.1% of scientists in the world in the field of Lipids, RNA vaccines and therapeutics and in nanomedicine.
Explore other speakers:
Dr César López-Camacho
The Jenner Institute, University of Oxford
Dr López-Camacho joined Oxford over a decade ago and his research centres on vaccine development against arthropod-borne pathogens spanning viruses transmitted by mosquitoes, ticks, and other vectors.
Dr Daragh Mcloughlin
Principal Scientist, Centre for Process Innovation (CPI)
Daragh specialises in formulation and delivery technologies, with a strong focus on lipid nanoparticle (LNP) systems and microfluidic manufacturing.
Dr Diego de Miguel
Manager of the Formulation Department, Certest Pharma
Dr. Diego de Miguel leads the Lipid Nanoparticle (LNP) Formulation Department at Certest Pharma, where he designs next-generation LNP platforms that broaden the therapeutic potential of mRNA vaccines and other nucleic-acid medicines.
Dr Bakul Gupta
CEO and Co-Founder, Deliver Bio
Dr Bakul Gupta is the CEO and Co-Founder of Deliver Biosciences, a preclinical stage biotech developing nanoparticle-based gene delivery vectors for in vivo cell reprogramming and gene editing.
Erdinc Sezgin, PhD
Professor, Karolinska Institute
Since 2020, Erdinc has been leading his independent lab as an Associate Professor at Karolinska Institutet and SciLifeLab. He is currently an EMBO Young Investigator and a Visiting Faculty at University of Oxford.
Dr Fred Campbell
CEO, Outfox Bio
At Outfox Bio Fred's commitment is not only to develop cheaper, safer and more effective LNP-based gene delivery systems but crucially to ensure a clear and viable route to patients so as to maximize the impact of the coming gene therapy revolution
Dr Heinrich Haas
CTO, Neovac Ltd
Heinrich focuses on advanced approaches for nanoparticle development and control.
Professor Neill Liptrott
Chair of Pharmacology and Immunocompatibility, The University of Liverpool
Neil's research explores immune interactions with complex medicines, biotherapeutics and biomaterials.
Dr Patrícia Monteiro
Senior Scientist, AstraZeneca
Patrícia's work spans from formulation of small molecules to the development of delivery systems for in vivo CAR-T cell generation, with a strong focus on the design, development, and optimisation of targeted lipid nanoparticles (tLNPs).
JunProf. Dr. Philipp Uhl
Group Leader, Lipoid-endowed Professorship, Heidelberg University, Institute of Pharmacy and Molecular Biotechnology
In Philipp's research, he primarily focuses on the development of optimized antibiotics formulations as well as on delivery systems for oral delivery of macromolecular drugs in general.
Professor Avi Schroeder
Professor of Chemical Engineering, Technion–Israel Institute of Technology
Avi is the recipient of more than 40 national and international recognitions, including being named a Fellow of the Royal Society of Chemistry, a KAVLI Fellow, and being awarded the Intel Nanotechnology Award, the TEVA Pharmaceuticals Award, and the Wolf Foundation Krill Award.
Dr Richard A. Campbell
Senior Lecturer in Physical Pharmacy, University of Manchester
Richard has expertise in resolving complex soft matter interactions at fluid interfaces through combined and novel applications of neutron and optical reflectometry.
Dr Christophe Delehedde
Scientist, Sanofi
Christophe's research centers on the design and characterization of targeted lipid nanoparticles aimed at precise immune cell engagement.
Justin R Martin, PhD
Lead Development Scientist, Croda Pharma
Justin spearheads the development and scale-up of lipid production processes under GMP (compliant) conditions.
Michael Hai Luu Nguyen, PhD
VP of Business Development, Helix Biotech
At Helix Biotech, Michael is now applying his skills to help advance RNA and lipid nanoparticle technologies for therapeutic delivery.
Professor Robin Shattock
Professor of Mucosal Infection and Immunity, Imperial College
Robin Shattock is Professor of Mucosal Infection and Immunity at Imperial College, London with over 30 years’ experience in research and development of vaccines and anti-infectives.
Tim Leaver
Senior Director Nanomedicine Services and Lipids, Cytiva
At Cytiva, Tim's focus is to bring together a full suite of technologies, services and subject matter experts to ensure we can make every scientist a genomic developer.
Professor Yvonne Perrie
Head of Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
Yvonne's research focuses on developing drug and vaccine delivery systems to address real-world healthcare challenges